PUBLISHER: iData Research Inc. | PRODUCT CODE: 2133420
PUBLISHER: iData Research Inc. | PRODUCT CODE: 2133420
The global biceps tenodesis market was valued at just over $135 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 4.9%, reaching just under $190 million by 2032.
This report covers suture anchors and tenodesis screws used in biceps tenodesis procedures. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Two clinical trends are supporting market growth. First, growing evidence favoring tenodesis over tenotomy is driving a partial conversion of biceps tendon repairs toward tenodesis devices, primarily because tenotomy carries a higher rate of cosmetic deformity, including the Popeye sign. Second, the broader shift from SLAP repair to biceps tenodesis is adding incremental procedure volume, as surgeons increasingly find that tenodesis delivers lower complication rates and higher rates of return to preinjury activity.
Tenotomy remains a relevant alternative for older and lower-demand patients due to its shorter operative time and simplified rehabilitation, which limits the pace of full conversion. The migration of procedures to ambulatory surgery centers (ASCs) is also placing downward pressure on device pricing, constraining ASP growth across both product categories despite rising procedural demand.
Market Overview
The global biceps tenodesis market is a focused, specialized segment within shoulder repair, centered on the fixation of the long head of the biceps tendon to the humerus. While total market value is modest relative to larger orthopedic categories, the market is growing steadily as clinical evidence supports tenodesis outcomes and procedure volumes increase through gradual conversion from tenotomy and SLAP repair. Both suture anchors and tenodesis screws serve as core fixation devices, with product development oriented toward fully arthroscopic delivery, improved biocompatibility, and expanded procedural versatility.
The comparison between tenodesis and tenotomy is the most direct commercial driver in this market. A 2025 multicenter trial confirmed that both procedures achieve comparable functional outcomes, but patients undergoing tenotomy experience a significantly higher incidence of cosmetic deformity compared to those receiving tenodesis. This difference is driving a partial conversion toward tenodesis devices, particularly among younger and more active patients who prioritize preservation of supination strength and cosmetic appearance. Tenotomy remains a suitable and frequently chosen option for older or lower-demand patients due to its shorter operative time and the absence of fixation hardware requirements, which limits the pace of conversion to tenodesis procedures.
The shift from SLAP repair to biceps tenodesis is also contributing to procedure volume growth within this market. Clinical data in 2025 indicates more favorable patient outcomes following tenodesis compared to SLAP repair, with lower complication rates and higher return to preinjury activity levels. As biceps tenodesis is increasingly recognized as the preferred standard for managing long head of biceps pathology, the suture anchors and interference screws used in these procedures are capturing a larger share of the broader surgical shoulder market.
A substantial portion of biceps tendon repairs now take place within ambulatory surgery centers. These facilities prioritize efficient and economical arthroscopic techniques and operate with leaner financial profiles than traditional hospital settings. This shift has placed downward pressure on device pricing, limiting ASP growth across both suture anchor and tenodesis screw categories. Product development in response to this environment has focused on arthroscopic compatibility, procedural efficiency, and value-oriented materials such as biocomposite and PEEK that meet clinical standards without premium pricing burdens.
Market Drivers
Conversion from Tenotomy to Tenodesis
Clinical evidence in 2025 continues to favor tenodesis over tenotomy for biceps tendon repair in active and cosmetically conscious patient populations. A 2025 multicenter trial confirmed that while both procedures achieve comparable functional outcomes, patients undergoing tenotomy experience a meaningfully higher incidence of the Popeye sign compared to those receiving tenodesis. This cosmetic difference is a key factor driving partial conversion of biceps repairs toward tenodesis devices. Tenotomy remains a reasonable choice for older or lower-demand patients given its shorter operative time, reduced bone trauma, and simplified recovery, but for patients who place value on supination strength and physical appearance, tenodesis is the increasingly preferred approach. This conversion trend is the primary source of incremental procedure volume growth in the market.
Tenodesis versus SLAP Repair
The broader clinical migration from SLAP repair to biceps tenodesis is adding procedural volume to the biceps tenodesis market. SLAP repair was previously the surgical standard for managing biceps-related shoulder pain, but clinical experience and longitudinal outcome data have shifted surgeon preference toward tenodesis. Clinical data in 2025 indicates that biceps tenodesis offers lower complication rates, fewer reoperations, and higher rates of return to preinjury activity levels compared to SLAP repair. As this preference becomes more firmly embedded across clinical settings globally, biceps tenodesis is capturing a larger share of shoulder repair procedures, creating demand for the suture anchors and interference screws central to this indication.
Market Limiters
Outpatient Settings and ASC Pricing Pressure
A substantial number of biceps tendon repairs now occur within ambulatory surgery centers, which operate with leaner financial profiles than traditional hospital settings and prioritize economical arthroscopic techniques to maintain profitability. The migration of procedures to these facilities has exerted sustained downward pressure on device pricing, constraining ASP growth across both suture anchor and tenodesis screw categories. ASC administrators frequently negotiate aggressively on consumable pricing and may standardize on lower-cost product options to control costs. This operating environment limits the ability of manufacturers to pass on price increases tied to product innovation, moderating overall market value growth despite a rising procedure count.
Tenotomy as a Simpler Surgical Alternative
Biceps tenodesis is a more complex and time-consuming procedure than tenotomy, and tenotomy remains a widely accepted alternative for specific patient demographics. Tenotomy minimizes bone trauma by eliminating the need for fixation hardware, reduces operative time, and simplifies post-operative rehabilitation. For older or lower-demand patients where preservation of supination strength and avoidance of cosmetic deformity are less critical priorities, tenotomy is frequently the preferred choice. The continued viability and clinical acceptance of this simpler alternative limits the full conversion of biceps repairs to tenodesis procedures, placing a natural ceiling on total suture anchor and tenodesis screw demand within this indication.
Market Coverage and Data Scope
Markets Covered and Segmentation
Competitive Analysis
Arthrex continued to lead the biceps tenodesis market in 2025, maintaining a dominant position through consistent product development across both suture anchor and interference screw categories. The company offers the SwiveLock Tenodesis Implant line, designed for both proximal and distal procedures and available in various eyelet configurations to support diverse surgical techniques. The FiberTak Biceps Implant System provides a high-strength, all-suture anchor solution designed to minimize bone removal during repair. Arthrex also offers the Tenodesis Screw in BioComposite and PEEK materials, which remains a standard for secure tendon-to-bone fixation in the humerus and addresses the full spectrum of clinical tenodesis approaches.
Smith and Nephew held the second position in the biceps tenodesis market in 2025. The company sells the BICEPTOR Tenodesis System, which supports fully arthroscopic surgeries using BIOSURE PK Interference Screws. For suture anchor applications in biceps tenodesis, Smith and Nephew offers the Q-FIX all-suture product, giving the company coverage across both core device categories in the market.
DePuy Synthes remained the third leading competitor in 2025. The company offers the MILAGRO Advance Interference Screw in BIOCRYL RAPIDE biocomposite and PEEK materials. The HEALIX product line includes suture anchors across PEEK, biocomposite, and metal material types. In early 2025, DePuy Synthes expanded this portfolio with the TIGHT-N anchor, an inlay tendon docking device designed to protect the tendon from laceration while delivering high-strength sub-cortical fixation.
Technology and Practice Trends
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
The Global Biceps Tenodesis Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, prioritize product development investments, and plan for growth across all major global regions.